CITIUS ONCOLOGY, INC.

For the period ended Sep 30, 2025. Filed Dec 23, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Dec 23, 2025

CTOR$0.55+7.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

SEPTEMBER 30, 2025 AND 2024

	2025	2024
Current Assets:
Cash and cash equivalents	$3,924,908	$112
Inventory	22,286,693	8,268,766
Prepaid expenses	1,331,280	2,700,000
Total Current Assets	27,542,881	10,968,878
Other Assets:
In-process research and development	73,400,000	73,400,000
Total Other Assets	73,400,000	73,400,000
Total Assets	$100,942,881	$84,368,878
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$13,234,684	$3,711,622
License payable	22,650,000	28,400,000
Accrued expenses	4,093,124	—
Due to related party	9,513,771	588,806
Total Current Liabilities	49,491,579	32,700,429
Deferred tax liability	2,784,960	1,728,000
Note payable to related party	3,800,111	3,800,111
Total Liabilities	56,076,650	38,228,540
Stockholders’ Equity:
Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding	—	—
Common stock - $0.0001 par value; 400,000,000 and 100,000,000 shares authorized at September 30, 2025 and 2024, respectively; 83,513,442 and 71,552,402 shares issued and outstanding at September 30, 2025 and 2024, respectively	8,351	7,155
Additional paid-in capital	108,897,836	85,411,771
Accumulated deficit	(64,039,956)	(39,278,587)
Total Stockholders’ Equity	44,866,231	46,140,339
Total Liabilities and Stockholders’ Equity	$100,942,881	$84,368,878

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.